Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Gross Margin of 40.5% for Q1 2026, up 2710.0% year-over-year from 1.44% in Q1 2025, and down 19.5% quarter-over-quarter from 50.32% in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Gross Margin for 4 consecutive years, with 40.5% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 2710.0% year-over-year to 40.5%; the TTM figure through Mar 2026 stood at 36.71% (up 413.0% YoY), while the FY2025 annual figure was 34.28%, down 889.0% from the prior year.
- Gross Margin fell to 40.5% in Q1 2026 per IOVA's latest filing, from 50.32% in the prior quarter.
- Across five years, Gross Margin topped out at 1211.41% in Q4 2023 and bottomed at 915.52% in Q1 2024.
- Historically, Gross Margin has averaged 87.01% across 4 years, with a median of 26.95% in 2025.
- Annual changes were most pronounced in 2024 — Gross Margin tumbled 116269 bps — and 2025, when it jumped 92892 bps.
- Iovance Biotherapeutics' Gross Margin stood at 1211.41% in 2023, then sank by 96 bps to 48.72% in 2024, then gained by 3 bps to 50.32% in 2025, then slipped by 20 bps to 40.5% in 2026.
- Business Quant data shows IOVA's Gross Margin at 40.5% in Q1 2026, 50.32% in Q4 2025, and 42.96% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | 56.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.10% |
| Mar 31, 2026 | 40.50% |
| Dec 31, 2025 | 50.32% |
| Sep 30, 2025 | 42.96% |
| Jun 30, 2025 | 18.47% |
| Mar 31, 2025 | 13.40% |
| Dec 31, 2024 | 48.72% |
| Sep 30, 2024 | 46.17% |
| Jun 30, 2024 | -0.84% |
| Mar 31, 2024 | -915.52% |
| Dec 31, 2023 | 1,211.41% |
| Sep 30, 2023 | -825.37% |
| Jun 30, 2023 | -761.34% |